Voluntary Financial Disclosure Guidelines Being Considered By PhRMA
Executive Summary
PhRMA is considering the development of voluntary guidelines on financial interest disclosure for researchers publishing study results as part of a strategy to improve the pharmaceutical industry's image in a climate in which questions have arisen about investigator-sponsor relationships.
You may also be interested in...
BIO Wants Waxman/Hatch Reform Isolated From Generic Biologics
BIO hopes that jurisdictional considerations will prevent the Senate Judiciary Committee's discussion of Waxman/Hatch revisions from becoming a forum for arguments over an FDA approval process for generic versions of biological products.
BIO Wants Waxman/Hatch Reform Isolated From Generic Biologics
BIO hopes that jurisdictional considerations will prevent the Senate Judiciary Committee's discussion of Waxman/Hatch revisions from becoming a forum for arguments over an FDA approval process for generic versions of biological products.
Pharmacoeconomic Analysis Methods Should Be Standardized - JAMA
Standardized methods of pharmacoeconomic analysis should be developed to better enable study comparisons, Sheldon Krimsky, PhD, Tufts University, advocated in an Oct. 20 Journal of the American Medical Association editorial.